NasdaqGS - Nasdaq Real Time Price USD
Incyte Corporation (INCY)
At close: 4:00 PM EST
After hours: 4:45 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
4,075,860.00
3,695,649.00
3,394,635.00
2,986,267.00
2,666,702.00
Cost of Revenue
293,400.00
255,000.00
207,000.00
150,991.00
131,300.00
Gross Profit
3,782,460.00
3,440,649.00
3,187,635.00
2,835,276.00
2,535,402.00
Operating Expense
3,776,286.00
2,790,939.00
2,596,009.00
2,234,758.00
2,775,643.00
Operating Income
6,174.00
649,710.00
591,626.00
600,518.00
-240,241.00
Net Non Operating Interest Income Expense
166,479.00
169,797.00
37,266.00
8,739.00
-2,174.00
Other Income Expense
101,155.00
14,691.00
-99,739.00
-38,813.00
10,247.00
Pretax Income
273,862.00
834,215.00
529,116.00
570,444.00
-232,218.00
Tax Provision
241,380.00
236,616.00
188,456.00
-378,137.00
63,479.00
Net Income Common Stockholders
32,482.00
597,599.00
340,660.00
948,581.00
-295,697.00
Diluted NI Available to Com Stockholders
32,482.00
597,599.00
340,660.00
948,581.00
-295,697.00
Basic EPS
0.10
2.67
1.53
4.30
-1.36
Diluted EPS
0.09
2.65
1.52
4.27
-1.36
Basic Average Shares
214,879.25
223,628.00
222,004.00
220,428.00
218,073.00
Diluted Average Shares
215,433.25
225,928.00
223,958.00
222,074.00
218,073.00
Total Operating Income as Reported
-52,877.00
620,525.00
579,440.00
585,777.00
-263,676.00
Total Expenses
4,069,686.00
3,045,939.00
2,803,009.00
2,385,749.00
2,906,943.00
Net Income from Continuing & Discontinued Operation
32,482.00
597,599.00
340,660.00
948,581.00
-295,697.00
Normalized Income
-47,430.45
587,080.24
404,891.92
976,914.49
-286,236.93
Interest Income
169,144.00
172,348.00
39,932.00
10,647.00
--
Interest Expense
2,665.00
2,551.00
2,666.00
1,908.00
2,174.00
Net Interest Income
166,479.00
169,797.00
37,266.00
8,739.00
-2,174.00
EBIT
276,527.00
836,766.00
531,782.00
572,352.00
-230,044.00
EBITDA
364,804.00
919,426.00
599,637.00
630,196.00
-178,237.00
Reconciled Cost of Revenue
293,400.00
255,000.00
207,000.00
150,991.00
131,300.00
Reconciled Depreciation
88,277.00
82,660.00
67,855.00
57,844.00
51,807.00
Net Income from Continuing Operation Net Minority Interest
32,482.00
597,599.00
340,660.00
948,581.00
-295,697.00
Total Unusual Items Excluding Goodwill
101,155.00
14,691.00
-99,739.00
-38,813.00
-12,959.00
Total Unusual Items
101,155.00
14,691.00
-99,739.00
-38,813.00
-12,959.00
Normalized EBITDA
263,649.00
904,735.00
699,376.00
669,009.00
-165,278.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
21,242.55
4,172.24
-35,507.08
-10,479.51
-3,498.93
12/31/2020 - 11/4/1993
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
KURA Kura Oncology, Inc.
10.80
+7.36%
APLS Apellis Pharmaceuticals, Inc.
30.77
+10.88%
HALO Halozyme Therapeutics, Inc.
49.00
+7.22%
MDGL Madrigal Pharmaceuticals, Inc.
347.45
+5.53%
PTGX Protagonist Therapeutics, Inc.
46.46
+11.55%
ALNY Alnylam Pharmaceuticals, Inc.
244.89
-0.77%
NTLA Intellia Therapeutics, Inc.
14.30
+3.62%
CYTK Cytokinetics, Incorporated
49.10
+3.00%
SNDX Syndax Pharmaceuticals, Inc.
16.09
+3.14%
PYXS Pyxis Oncology, Inc.
1.9000
-9.52%